T Szucs
04.01.2012
Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis
Jörger M, Matter-Walstra K, Früh M, Kühnel U, Szucs T, Pestalozzi B, Schwenkglenks M. Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis. Ann Oncol 2012; 22:567-574.
04.01.2012Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis
04.01.2012Ann Oncol 2012; 22:567-574
Jörger Markus, Matter-Walstra K, Früh Martin, Kühnel U, Szucs T, Pestalozzi B, Schwenkglenks M
Weiter
13.09.2010
Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis
Jörger M, Matter-Walstra K, Früh M, Kühnel U, Szucs T, Pestalozzi B, Schwenkglenks M. Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis. Ann Oncol 2010; 22:567-74.
13.09.2010Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis
13.09.2010Ann Oncol 2010; 22:567-74
Jörger Markus, Matter-Walstra K, Früh Martin, Kühnel U, Szucs T, Pestalozzi B, Schwenkglenks M
Weiter